和誉-B(02256.HK)：完成口服小分子PD-L1抑制剂ABSK043联合戈来雷塞治疗NSCLC II期临床首例患者给药

Core Viewpoint - The announcement by He Yu-B (02256.HK) regarding the completion of the first patient dosing in a Phase II clinical study for its oral small molecule PD-L1 inhibitor ABSK043 in combination with Shanghai Ailis Pharmaceutical Technology Co., Ltd.'s KRAS G12C inhibitor, Goleirese, for treating KRAS G12C mutation-positive non-small cell lung cancer (NSCLC) [1] Group 1 - He Yu-B has initiated a Phase II clinical study for ABSK043 in combination with Goleirese [1] - The study targets patients with KRAS G12C mutation-positive NSCLC [1] - The first patient has been dosed in this clinical trial [1]